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ABSTRACT  
In this article, we have discussed about Types (primary, secondary, isolated, white coat, malignant, resistant and pulmonary hypertension), 
classification, adverse drug reactions of antihypertensive drugs (beta-blocker induce psoriasis and calcium channel blocker cause peripheral 
oedema. ACE inhibitor produce ankle oedema and thiazide diuretics causes hypenatremia and also hyperglycaemia. These are some of the 
serious adverse drug reactions associated with patients who are being treated with these drugs), measurement, management, diagnosis and 
associated diseases (e.g. diabetes mellitus, heart disease, cerebrovascular disease) lastly concluded about the herbal approach for management 
of hypertension  . 
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1. INTRODUCTION  
Persistent elevation in blood pressure is known as 
hypertension. In hypertension, systolic blood pressure (SBP) 
is greater than 140 mmHg or diastolic blood pressure (DBP) 
is greater than 90 mmHg.14 
Table 1: Categories/stages of hypertension: (14) 
Category SBP                        DBP 
Normal <120 <80 
Pre-hypertension 120-139 80-89 
Stage-1 140-159 90-99 
Stage-2 >160 >100 
 
Blood pressure (BP) = cardiac output (CO) × peripheral 
vascular resistance 
Cardiac output (CO) = heart rate (H.R.) × stroke volume 
(SV) 
Heart rate: number of beats per minute (72). 
Stroke volume: The amount of blood pumped in 1 heart 
beat (60ml). 
1.1 Epidemiology 
Hypertension is public health problem in both developing 
and developed countries and affecting about 20% adult 
population shown in figure 1. Worldwide, 7.5 million 
premature deaths (about 13.5% of the global total) were due 
to hypertension. About 55% of stroke and 48% of ischaemic 
heart diseases worldwide attributable to high blood 
pressure. Prevalence of hypertension in India is about 27% 
in men and 24% in women. According to statistics cases of 
hypertension increased 10 times in last 4 decades in rural 
India and almost 30 times in urban India 1. 
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Fig. 1 Negative impact of hypertension 
 
1.2 Symptoms 
Hypertension has no sign and symptoms. Therefore, it is also 
called as “silent killer”. A small amount of people may 
experience symptoms such as:  
 Severe Headache 
 Vomiting  
 Nosebleeds 
 Fatigue 
 Chest pain 
 Blurred vision 
But, these symptoms usually do not occur until blood 
pressure level reaches to life threatening stage 2.  
1.3 Causes of Hypertension 
 Hereditary  
 Obesity  
 High sodium intake 
 Psychological stress 
 stress 
Other factors also play a role: 
 Excessive alcohol drinking 
 Smoking  
 Physical inactivity 3. 
2. TYPES OF HYPERTENSION 
2.1 Primary hypertension/essential hypertension (95 to 
96%): it has no clear cause. But, frequent headache and 
tiredness is common. 
2.2 Secondary hypertension (4 to 5%): in secondary 
hypertension cause can be found and it includes: 
 Hormonal abnormalities 
 Too much salt in the diet 
 Alcohol consumption 
 Drugs can also cause secondary hypertension 
Example: over the counter drug (OTC), ibuprofen, 
Pseudoephedrine. 
If the cause is found, hypertension (HTN) can often be 
controlled 4. 
3. OTHER TYPES OF HYPERTENSION 
3.1 Isolated systolic hypertension: in this, systolic blood 
pressure tends to rise above 140 and diastolic blood 
pressure tends to fall and most common in people over the 
age 65. 
3.2 White coat hypertension: this term is used to denote 
individuals who have normal BP outside doctor’s office but, 
high BP in the medical environment therefore, the patients 
with this type of hypertension feel extremely stressed when 
they visit doctor’s office. 
3.3 Malignant hypertension: occur only in 1% of people 
with hypertension and in this DBP goes over 130, treated 
only in hospital. 
3.4 Resistant hypertension: if three different types of 
medications are prescribed by the doctor but, blood 
pressure is still too high. Then it is called resistant 
hypertension 5.  
3.5 Pulmonary hypertension: pulmonary hypertension 
means high blood pressure in the arteries going to lung. In 
healthy individuals, the BP in these arteries is much lower 
than in the rest of the body. 
Pulmonary arterial BP is about 25/10mmHg in healthy 
individuals. If this pressure exceeds 40/20 mmHg it means 
pulmonary hypertension is present 6. 
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4. CLASSIFICATION OF ANTI-HYPERTENSIVE 
DRUGS 
4.1 Diuretics 
Diuretics such as hydrochlorthiazide lower BP by increasing 
sodium and water excretion or urination. This cause a 
decrease in cardiac output and peripheral resistance and 
ultimately blood pressure decreases. Examples are 
Bumetanide, Furosemide, Hydrochlorthiazide, 
Spironolactone, Triamterene 14.  
4.2 Beta-blockers 
The β-blockers reduce blood pressure by decreasing cardiac 
output and also inhibit the release of rennin from the 
kidneys, thus decreasing the formation of angiotensin-2 and 
the secretion of aldosterone therefore volume of blood 
decreases which leads to decrease in BP. Examples are 
Atenolol, Propranolol, Labetolol, Timolol 14. 
4.3 ACE inhibitors 
These drug blocks the ACE that convert angiotensin-1 into 
angiotensin-2. Thus, ACE inhibitors decrease angiotensin-2 
level so, reduce constriction and also secretion of 
aldosterone that control the level of sodium and water ions. 
Hence, B.P. decreases. Examples are Captopril, Enalapril, 
Lisinopril, Quinapril, Ramipril 14. 
4.4 Angiotensin2-receptor antagonist (ARB) 
Angiotensin receptor blocker alternative to the ACE 
inhibitors. These drugs blocks the AT1 receptors, result in 
vasodilatation and also block aldosterone secretion. 
Examples are Candesartan, Irbesartan, Losartan, 
Telmisartan, Valsartan 14. 
4.5 Renin inhibitors 
Aliskiren directly inhibit rennin and thus, acts earlier in the 
rennin angiotensin aldosterone system than ACE inhibitors 
or ARBs. It decreass blood pressure about as effectively as 
ARBs, ACE inhibitors and thiazides. For example Aliskiren. 
But, aliskiren cause diarrhea at higher doses 14. 
4.6 Calcium channel blockers 
Calcium is responsible for contraction and the calcium 
channel antagonist block the inward movement of calcium 
by binding to L-type calcium channels in the heart, these 
cause vascular smooth muscles to relax or channel blockers 
lower B.P by reducing myocardial contractility. For example, 
Amlodipinem, Diltiazem, Felodipine, Nicardipine, Nifedipine, 
Verapamil 14. 
4.7 Alpha- blockers 
Alpha blockers block the α1 receptor. They decrease 
peripheral vascular resistance and lower arterial blood 
pressure by causing relaxation of both arterial and venous 
smooth muscles because these receptors are present on 
vascular smooth muscle. For example Prazosin, Doxazosin 14. 
4.8 Other  
Sodium nitroprusside: nitroprusside is administered 
intravenously and cause prompt vasodilation. It is capable of 
reducing BP in all the patients.but, nitroprusside is 
metabolized quickly and requires continuous infusion for 
the maintainance of its hypotensive action. For example 
Hydralazine(vasodilator) 14. 
 
Table 2: Commonly used antihypertensive drugs: 7. 
S.NO. CLASS GENERIC NAME DOSE(mg) BRAND NAME 
1. Diuretics Hydrochlorthiazide 
Indapamide 
furosemide 
12.5-50 
1.25-5 
200-400 
Hydrex 
Natrilex 
Lasix 
2. Beta-blocker Atenolol 
Metaprolol 
25-100 
50-200 
Blockium 
Betaloc 
3. Calcium antagonist Verapamil 
Diltiazem 
120-480 
90-240 
Tarka isoptin retard 
Tildium altiazem 
4. ACE inhibitors Captopril 
Enalapril 
Lisinopril 
50-150 
2.5-40 
10-40 
Capozide 
Ezapril 
Zestril 
5. ARB Losartan 
Valsartan 
Candesartan 
25-100 
80-320 
4-32 
Fortzar 
Co-diovan 
Atacand 
6. Alpha-blocker Prazosin 
Doxazosin 
1-16 
1-16 
Minipress 
Cardura 
7. Centrally acting 
drugs 
Methyldopa 
Clonidine 
500-2000 
0.1-1.2 
Aldomet 
Catapres 
 
5. ADVERSE EFFECTS OF ANTI HYPERTENSIVE 
DRUGS 
5.1 Hypokalemia 
Diuretics cause hypokalemia and it is treated by rational 
medication combination. Low dose thiazide combined with 
ACE or ARBs to maintain the potassium concentration 
sufficiently. 
 
5.2 Hyponatremia 
One of the most common problems with thiazide diuretics is 
hyponatremia. Those who develop hyponatremia should be 
changed to other class of drugs. If still diuretics are required 
a low dose of long acting loop diuretics (e.g. torsemide 2.5-
5mg daily) is effective. 
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5.3 Edema 
Antihypertensive medication induced edema is more 
common. Women may be particularly susceptible to calcium 
channel blocker induced edema. But, peripheral edema can 
be minimized by decreasing the dose. 
5.4 Erectile dysfunction 
It affects about 30% of men with hypertension. Both 
hypertension and erectile dysfunction are disorders of 
endothelial dysfunction. Preliminary evidence suggests that 
combination of phosphodiesterase type-5 inhibitors (PDE5) 
and alpha-blockers improve erectile dysfunction 8. 
5.5 Psoriasis 
The use of beta-blocker may result in psoriasis and if we 
substitute any other beta-blocker it may further cause skin 
lesions. If psoriasis is present only in localized area then, 
emollients can be helpful. 
5.6 Hyperglycaemia 
Hyperglycaemia is more common and severe adverse effect 
is seen with thiazide diuretics than other class of anti-
hypertensive drugs. Patient with diuretic induced 
hyperglycaemia are often considered as having type-2 
diabetes and are prescribed with oral anti-diabetic agent 9. 
6. B.P. MEASUREMENT 
6.1 Sphygmomanometer 
The sphygmomanometer was invented by Samuel Siegfried 
Karl Ritter Von Basch in the year 1881. 
Sphygmomanometer self-measurement of blood pressure 
device. 
6.2 Points to be considered during the measurement of 
B.P. 10. 
6.2.1 Posture of patient 
Allow the patient to be seated for few minutes before the 
measurement of blood pressure. B.P. should be measured 
when the patient in a relaxed state, the arm at the level of 
heart and the legs are not crossed. 
6.2.2 B.P. device 
The device should be validated. 
6.2.3 Cuff size 
The cough with bladder whose length is at least 80% of the 
arm circumference is preferable. 
6.2.4 Number of measurements 
At least two readings should be taken at each visit with an 
interval of at least 1 min. this will avoid the calculation error 
involved in averaging the two measurements. Due to 
variability of B.P. measurements the diagnosis of 
hypertension should be made only after multiple readings. 
 
Table 3: 
S.NO. Measurement error Effect on B.P. 
1. Back is not supported Diastolic blood pressure increased by 6mmHg 
2. Legs are crossed Systolic B.P. increased by 2-8mmHg  
3. Arm is not at the level of heart Increase B.P. by 10-12mmHg 
 
7. MANAGEMENT OF HYPERTENSION 11. 
Non pharmacological management plays an important role 
for the improvement of overall cardiovascular diseases. It 
include: 
7.1 Weight reduction: Dietary interventions to lower body 
weight also recommended for people with hypertension. 
Weight reducing diet reduces about 4.5/3.2mmHg blood 
pressure. 
7.2 Sodium intake: Reduce sodium intake sufficiently 
reduces B.P. in adults. A recent study has shown that 
reduction of sodium intake from 11.6g of salt to 3.8g of salt 
decrease the B.P. in asian people. 
7.3 Alcohol consumption: Alcohol consumption increases 
B.P. reducing alcohol intake reduce B.P. by 3.3/2mmHg. 
People who drink are advised to limit the consumption of 
alcohol. 
7.4 Regular physical activity: Increased physical activity 
has been shown to reduce blood pressure. Aerobic exercise 
of at least 150 min. per week is beneficial.  
7.5 Healthy eating: A diet rich in fruits, vegetables, low fat 
dairy products can lower B.P. DASH (dietary approaches to 
stop hypertension) diet significantly lower the B.P. and it 
include, Grains, Vegetables, Fruits, Low fat dairy foods, Nut, 
seeds, beans. 
7.6 Cessation of smoking: Smoking cessation is important 
in reducing global cardiovascular risk. 
7.7 Dietary potassium intake: Increase dietary potassium 
intake reduces B.P. in adults without adverse effect on blood 
lipid concentration. Dietary potassium can reduce B.P. by 
3.49/1.96mmHg and also lower the risk of stroke by 25% 
this can be achieved by eating fruits, vegetables, nuts and 
legumes. 
8. ASSOCIATED DISEASES WITH HYPERTENSION 
8.1 Diabetes mellitus 
Patient with diabetes mellitus should be initiated on drug 
therapy when the SBP is greater than 140mmHg. ACE 
inhibitors are used initially than calcium channel blockers 
and diuretics used as add on therapy. 
8.2 Heart disease 
Beta-blockers used in patient with hypertension and a 
recent myocardial infarction. In case of angina, beta-blockers 
and calcium channel blockers are prefer but, in patient with 
heart failure and hypertension thiazide diuretics are more 
preferable. 
8.3 Cerebrovascular disease 
Initiation of drug treatment should be considered with grade 
1 hypertension in patient with stroke history. Do not 
administer antihypertensive drugs in first 72 hours of 
ischemic stroke 12. 
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9. DIAGNOSIS OF HYPERTENSION: 
9.1 Measure B.P. in both the arms for the diagnosis of 
hypertension 
9.1.1 Repeat the measurements, if the difference in readings 
between arms is more than 15mmHg. 
9.1.2 Measure subsequent B.P. in the arm if the difference 
between the arms more than 15mmHg on the second 
measurement. 
9.2 When B.P. measurement is inside the clinic 
140/90mmHg or higher 
9.2.1 During the consultation take second measurement. 
9.2.2 Take third measurement if second is different from 
first 
9.3 Ambulatory blood pressure monitoring (ABPM) – if clinic 
blood pressure is between 140/90 and 180/120mmHg 
to confirm the diagnosis of hypertension. 
9.4 If ABPM is unsuitable for the person offer home blood 
pressure monitoring (HBPM) for the diagnosis of 
hypertension. 
9.5 When using ABPM ensure that at least 2 measurements 
taken per hour during the person’s waking hour (e.g. 
between 8.00 and 22.00). When using HBPM ensure 
that for each blood pressure recording, 2 consecutive 
measurements are taken 13. 
 
 
Patient presentation Patient presents with uncontrolled BP (>140/90) 
i. Check clinic blood pressure Controlled clinic blood pressure measurement: 
 Take a first measurement. 
 Take a second measurement, if BP is high. 
 If the last measurement is different from the first, take a third 
measurement. 
 The last two measurements recorded as a clinic BP. 
ii. Rule out white coat hypertension Refer for ambulatory BP monitoring, if blood pressure is 
uncontrolled. 
iii. Rule out non-adherence to medication  If BP is uncontrolled on ABPM consider: 
 Urine analysis 
 Directly observed dosing 
iv. Diagnosis Diagnosis of resistant hypertension can be made if BP is 
uncontrolled. 
 
10. NOVEL DRUG DELIVERY SYSTEM FOR HYPERTENSION 
S. N. Drug Delivery system/formulation 
approaches 
Applications 
1. Perindopril Mucosal administration route ODT: 
orodispersible tablets perindopril arginine 
Treatment of hypertension/heart 
failure15. 
2. Nitrendipine Sublingual mucosal route Effectively reduce B.P during first 45 
min15. 
3. Amlodipine Transmucosal administration Effective in coronary heart disease and 
hypertension15. 
4. Metaprolol Rectal administration of metaprolol 
tartrate 
Reduce B.P. significantly faster 
without severe side-effects15. 
5. Propranolol Rectal administration and 
Sublingual administation 
Sustain release of drug15. 
6. Carvedilol Solid lipid nanoparticles(SLN) 
And nanosuspensions 
Enhance bioavailability and protecting 
it from acidic environment16. 
7. Candesartan cilexitil Dendrimers and 
Nanosuspensions 
Improved water solubility16. 
8. Nifedipine Polymeric nanoparticles and 
Dendrimers 
Increase dissolution rate16. 
9. Felodipine Nanosuspensions/ 
Polymeric nanoparticles 
Control the release of drug16. 
10. Valsartan Proliposomes and self non –emulsifying 
drug delivery system 
*Bypass first pass metabolism 
*Prolong release of drug16. 
11. Nebivolol Polymeric nanoparticles Prolonged drug release16. 
12. Isradipine Transdermal penetration of drug Management of hypertension17. 
13. Olmesartan Nano-invasomes formulation/Transdermal 
delivery system(TDDS) 
Increase bioavailability17. 
14. Bosentan Nanoparticles endothelin receptor 
antagonist 
Effective in pulmonary hypertension18. 
15. Aliskiren Poly(D,L-lactide)(PLA) 
Oral gavage 
Prevent stroke by lowering high B.P18. 
16. Lacidipine Niosomes Helps to relax blood vessels18. 
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17. Captopril Chitosan polymer/oral route Improve survival after a heart attack 
18. Sildenafil Endotracheal administration Treat pulmonary hypertension18. 
19. Tacrolimus(TAC) Nanocompositae particles 
Endotracheal administration 
Pulmonary hypertension 
20. Silaenafil Poly (D,L-lactide-co-glycolide) 
nanoparticles 
Endotracheal administration 
Pulmonary HTN18. 
21. Cerivastatin Liposomes 
Endotracheal administration 
Pulmonary HTN18. 
22. Lercanidipine Proliposomes/ 
Oral dose using intragastric tube 
Immediate and long lasting (24h) 
reduction in systolic blood pressure19. 
23. Super- oxide dismutase 
(SOD) 
Lipose encapsulation/daily injections Reduce mean arterial pressure (MAP) 
by 50mmHg19. 
24. Covera-HS;XL tablet Osmotic control release oral drug delivery 
system(OROS)/ chronopharmaceuticals 
Prevent the dangerous surge of B.P in 
the early morning20. 
25. Verelan PM;XL release 
capsule 
Chronotherapeutic oral drug absorption 
system(CODAS) 
Manage hypertension in the 
morning20. 
26. Innopran ;XL tablets DIFFU CAS multiparticulate bead system 
comprised of multiple layers of drug, 
excipients and release controlling 
polymers 
Release is pH independent20. 
27. Pulsincap PULSINCAP rupturable system Release is pH independent20. 
28. Procardia  XL PROCARDIA XL sutained release tablet Decrease the frequency of chest pain 
attacks20. 
29. Cardizem LA; CEFORM  extended release tablet Production of uniformly sized and 
shaped microsphere20. 
30. ramipril Polymeric nanoparticles/chitosan Used to treat high B.P and congestive 
heart failure (CHF)20. 
31. Nisoldipine Solid lipid nanoparticles Lower high blood pressure21. 
32. Eplerenone (ARB) Oral route Treat high blood pressure21. 
33. Taladafil 
(phosphodiesterase-5-
inhibitor) 
Oral route Effective in pulmonary hypertension21. 
34. Imidapril (ACE) inhibitors By mouth Manage high blood pressure21. 
35. Azilsartan (angiotensin-1 
receptor blocker) 
Orally/40mg or 80mg Treat hypertension21. 
36. Macitentan (endothelin A 
receptor blocker) 
Orally/10mg Pulmonary hypertension21. 
37. Ambrisentan 
EARB(endothelinA 
receptor blocker) 
Film coated tablet/orally Pulmonary HTN21. 
38. Monoxidine(imidazolidine 
receptor blocker) 
Oral route Treat mild to moderate essential 
hypertension21. 
39. Cicletanine (endothelila 
nitric oxide synthase 
coupler) 
Orally It’s a diuretic drug for the treatment of 
hypertension21. 
 
 
11. NOVEL BRANDED DRUGS FOR THE TREATMENT OF HYPERTENSION 
S. No Drug Delivery system/formulation 
approaches 
Applications 
1 Flolan (prostacyclin derivative) Intravenous(I.V) Treatment of pulmonary arterial 
hypertension (PAH)22. 
2 Veletri (prostacyclin derivative) I.V Treatment of PAH22. 
3 Ventavis (prostacyclin derivative) Inhaled Treatment of PAH22. 
4 Remodulin (prostacyclin 
derivative) 
Subcutaneous (SC)/IV Treatment of PAH22. 
5 Tyvaso (prostacyclin derivative) Inhaled Treatment of PAH22. 
6 Tracleer (endothelin receptor 
antagonist/ERA) 
Oral Treatment of PAH22.. 
7 Letairis (ERA) Oral Treatment of PAH22. 
8 Revatio (PDE-5-inhibitor) Oral Treatment of PAH22. 
9 Adcirca (PDE-5-inhibitor) Oral Treatment of PAH22. 
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12. NEW COMBINATION THERAPY 
S. No Drug Delivery system/ 
formulation approaches 
Applications 
1 Sildenafil + 
Epoprostenol 
Oral /IV Treatment of PAH22. 
2 Iloprost + Bosentan Inhaled /oral For the treatment of idiopathic pulmonary arterial 
hypertension (IPAH)22. 
 
13. HERBAL DRUGS AS BOOM FOR THE 
MANAGEMENT OF HYPERTENSION: 
 The use of herbal medicines throughout the world 
exceeds as compare to conventional drugs by two to 
three times. 
 It is the oldest form of health care for the prevention 
and treatment of illness.  
 Herbal drugs are phytochemical compounds used for 
the treatment of many diseases such as hypertension 
because herb has active ingredients which act as drug. 
 Herbal drugs are less expensive than synthetic drugs 
and people in the rural area mostly used these drugs 
due to less side effects 23. 
 Herbal drugs also have different pharmacokinetic and 
pharmacodynamic properties which leads to 
therapeutic  responses. 
13.1 Advantages of Herbal Medicines: 
I. Easily available. 
II. Safe and effective. 
III. Environmental friendly. 
IV. Patient compliant. 
V. Fewer side effects as compared to allopathic 
medicines. 24. 
 
 
13.2. Herbal drugs which are used as antihypertensive agents: 
S.No. Drug (common 
name) 
Botanical Name Pharmacological class 
1. Lotus  Nelumbo nucifera Vasodilator25.  
2. Ginseng  Panex ginseng Vasodilator 25. 
3. Garlic  Allium sativum ACE inhibitors25. 
4. Snake root Rouwolfia serpentina Vasodilator25. 
5. Ginger  Gingiber officinalis  Vasodilator25. 
6. Ginko  Ginko biloba Vasodilator25.  
7. Hawthorn  Crataegus oxycantha Vasodilator25. 
8. Punarnava  Boerhavia diffusa Diuretic25. 
9. Ashwagandha  Withania somnifera Diuretic25. 
10. Arjuna  Termenalia arjuna Diuretic25. 
11. Black cumin seeds  Nigella sativa  Centrally acting25. 
12. Alpinia  Alpinia zerumbet Diuretic 25. 
13. Raisins  Vitis vinifera  Vasodilator25.  
14. Olive leaf Olea europea Vasodilator25. 
15. Beetroot  Beta vulgaris Nitrodilator25.  
16. Tea  Camellia sinensis Nitrodilator/diuretic26.  
17. Saffron  Crocus sativus  Calcium channel blocker26. 
18. Roselle  Hibiscus sabdariffa Calcium channel blocker/vasodilator26. 
19. King of bitter  Andrographis paniculata Nitrodilar /ACE-inhibitor26. 
20. Celery  Apium graveolens Calcium channel blocker26. 
 
 
14. CONCLUSION 
The use of combination therapy as first line treatment will 
help more patients. This review is associated with treatment, 
management, adverse effects of drugs and diagnosis mainly. 
There is need for safe and effective therapies to achieve 
recommended blood pressure targets. This review article 
also provides help in the detection of B.P. and in the 
selection of particular antihypertensive drug with herbal 
drugs.
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